Our mission and values

Our mission

We seek to alleviate human suffering with life-changing medicines.

Our core values

We strive to uphold our core values every day, and we recognize and celebrate these ideals together in many ways throughout the year.

Patients First

We maintain intense focus on improving patients’ lives

Thoughtfulness

We explore creative approaches, daring to make well-thought-out decisions and owning the outcomes

Urgency

We solve complex problems rapidly, with attention and care

Trust

We collaborate to build and maintain a cohesive team that leads with integrity as well as mutual respect of lived experiences, viewpoints and diverse talents

Optimism

We pursue transformative therapies that we believe will make a difference

Our approach begins with a focus on understanding root causes of disease, then designing and optimizing highly selective and potent therapies that target these mechanisms.

Learn more

Our story

2011

Led by the pioneers of highly successful kinase inhibitors including Gleevec® (imatinib), our scientific founders launched our company with a vision to revolutionize how precision therapies are discovered and developed.

2011-2014

Our foundational work focused on the development of a proprietary library of novel compounds that are fully annotated against the human kinome. Today, this library remains a key tool for our successful drug discovery efforts.

2015

We launched an initial public offering on the Nasdaq stock exchange under the ticker BPMC.

2018

We announced a strategic collaboration with CStone Pharmaceuticals to develop and commercialize clinical-stage therapeutic candidates, including avapritinib and pralsetinib, in Mainland China, Hong Kong, Macau and Taiwan.

2019

We announced an exclusive, worldwide license agreement with Ipsen for Clementia Pharmaceuticals, a subsidiary of Ipsen, to develop and commercialize fidrisertib (formerly known as BLU-782 or IPN60130) for the treatment of fibrodysplasia ossificans progressiva.

2020

We received approval of AYVAKIT® (avapritinib) from the U.S. Food and Drug Administration for the treatment of PDGFRA exon 18 mutant gastrointestinal stromal tumors, including PDGFRA D842V mutations.

2020

We announced a global collaboration agreement with Roche to develop and commercialize GAVRETO® (pralsetinib) for patients with RET-altered cancers, including $775 million in upfront payments plus potential milestones and royalties.

2020

We received approval of GAVRETO® (pralsetinib) from the U.S. Food and Drug Administration for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer and patients with advanced or metastatic RET fusion-positive thyroid cancer.

2020

We received conditional marketing authorization of AYVAKYT® (avapritinib) from the European Commission for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors.

2021

We received approval of AYVAKIT® (avapritinib) from the U.S. Food and Drug Administration for the treatment of advanced systemic mastocytosis, including aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia.

2022

We announced plans to expand our scientific platform to include targeted protein degradation, a therapeutic modality that complements and leverages our capability and expertise in developing small molecule precision therapies. In association with these plans, we announced a strategic collaboration with VantAI to advance novel targeted protein degrader therapies.

2022

We received marketing authorization of AYVAKYT® (avapritinib) from the European Commission for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least one systemic therapy.

2022

We announced a transformative $1.25 billion strategic financing collaboration with Sixth Street and Royalty Pharma, bringing significant non-dilutive, low-cost capital to drive innovation and growth.

2023

We received approval of AYVAKIT® (avapritinib) from the U.S. Food and Drug Administration for the treatment of adults with indolent systemic mastocytosis.

2023

We received approval of AYVAKYT® (avapritinib) from the European Commission for the treatment of adult patients with indolent systemic mastocytosis with moderate to severe symptoms inadequately controlled on symptomatic treatment.

2024

We announced a definitive agreement with Rigel Pharmaceuticals granting Rigel the U.S. rights for GAVRETO® (pralsetinib), upon the termination of our global collaboration with Roche for GAVRETO, enabling continued access to GAVRETO to patients in the U.S.